EGFR突变局部晚期非小细胞肺癌脑转移风险增加
该研究对2002至2014年255例局部晚期非小细胞肺癌(LA-NSCLC)患者进行肿瘤基因分型,采用竞争风险分析(以死亡为竞争事件)评估脑转移风险。多因素分析显示EGFR突变与脑转移风险显著相关(HR 2.04,95%CI 1.22-3.39,p=0.006),3年和5年累积脑转移发生率在EGFR突变患者中更高(33.3% vs 23.2%,43.8% vs 24.2%,p=0.006)。结论认为EGFR突变LA-NSCLC患者接受标准综合治疗后脑转移可能性显著增高,独立于总生存延长。
要点
- EGFR突变LA-NSCLC患者脑转移风险显著增高(HR 2.04,95%CI 1.22-3.39,p=0.006)。
- 3年和5年累积脑转移发生率EGFR突变组分别为33.3%和43.8%,高于野生型组的23.2%和24.2%。
- 该高危基因亚组可能受益于常规脑MRI监测以早期挽救治疗。
核心结论
- EGFR突变LA-NSCLC患者接受标准综合治疗后脑转移可能性显著增高,独立于总生存延长。
研究设计与样本
- 2002至2014年间255例LA-NSCLC患者接受EGFR、ALK和/或KRAS肿瘤基因分型,其中180例有随访脑影像。
- 采用累积发生率和Fine-Gray回归分析临床变量(包括基因型)与脑转移风险,以死亡为竞争事件。
主要发现
- EGFR、ALK和KRAS异常肿瘤比例分别为17%、4%和28%。
- 中位随访68个月。
- 多因素分析显示EGFR突变与脑转移风险显著相关(全队列HR 2.04,95%CI 1.22-3.39,p=0.006;脑影像随访亚组HR 1.91,95%CI 1.17-3.13,p=0.01)。
- EGFR突变患者3年和5年累积脑转移发生率分别为33.3% vs 23.2%和43.8% vs 24.2%(p=0.006)。
临床怎么用
- EGFR突变LA-NSCLC患者接受标准综合治疗后,可考虑常规脑MRI监测以早期发现脑转移。
- 早期发现脑转移后可行靶向系统治疗和/或放疗挽救。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Small studies of primarily metastatic non-small cell lung cancer (NSCLC) have suggested an association between EGFR mutation (EGFR+) and likelihood of brain metastasis. However, these studies are confounded by follow-up time bias. We performed a competing risk analysis of brain metastasis in a more uniform locally advanced NSCLC (LA-NSCLC) cohort with known tumor genotype. MATERIALS AND METHODS: Between 2002 and 2014, 255 patients with LA-NSCLC underwent tumor genotyping for EGFR, ALK and/or KRAS (180 patients had follow-up brain imaging). Cumulative incidence and Fine-Gray regression were performed on clinical variables including genotype and risk of brain metastasis, with death as a competing event. RESULTS: The proportion of tumors with aberrations in EGFR, ALK and KRAS were 17%, 4% and 28%, respectively. The median follow-up was 68 months. On multivariate analysis, EGFR+ was significantly associated with risk of brain metastasis in the full patient cohort (HR 2.04, 95% CI 1.22-3.39, p = 0.006) as well as in the subset of patients with brain follow-up imaging (HR 1.91. 95% CI 1.17-3.13, p = 0.01). This translated to a higher cumulative incidence of brain metastasis in EGFR+ patients at 3 and 5 years (33.3% vs. 23.2 and 43.8% vs. 24.2%, p = 0.006). CONCLUSION: Patients with EGFR+ LA-NSCLC have a significantly higher likelihood of developing brain metastasis after standard combined modality therapy, independent of their longer overall survival. This high-risk genotypic subgroup may benefit from routine surveillance with brain MRI to allow early salvage with targeted systemic- and/or radiation-therapies.
引用
- Mitra D, Chen YH, Li R, et al. EGFR mutant locally advanced non-small cell lung cancer is at increased risk of brain metastasis. Clin Transl Radiat Oncol. 2019. PMID: 31341973. doi:10.1016/j.ctro.2019.06.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。